Denosumab Osteoporosis Dialysis Hypocalcaemia Risk — ESENeph MCQ

Instant feedback + full explanation. One question, done properly.

HardHaemodialysisDenosumab Osteoporosis Dialysis Hypocalcaemia RiskESENeph

A 58-year-old man with CKD G5D on haemodialysis has been anticoagulated with warfarin for AF. He develops unprovoked vertebral compression fractures. DEXA shows T-score -3.2 (osteoporosis). PTH is 25 pmol/L (within KDIGO target). Aluminium level is normal. What is the MOST appropriate treatment for osteoporosis in this dialysis patient?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: E — Denosumab with intensive calcium monitoring

Bisphosphonates (alendronate, zoledronic acid) are relatively contraindicated in dialysis patients because: (1) they accumulate in CKD due to renal excretion; (2) they can cause adynamic bone disease by over-suppressing turnover; (3) atypical fractures risk with long-term use. Denosumab (anti-RANKL antibody) is an alternative that does not require renal clearance. However, in dialysis patients, denosumab causes severe hypocalcaemia (because the kidneys cannot compensate and PTH response is often blunted), requiring INTENSIVE calcium and calcitriol supplementation with frequent monitoring (at least weekly calcium checks for the first month). This is manageable but requires a structured monitoring protocol. Teriparatide is avoided in renal osteodystrophy.

Reference: KDIGO 2024 – CKD-MBD; NICE 2017 – Osteoporosis; Dave et al 2015 – Denosumab in Dialysis